CClinicalTrials.gg
RecruitingNCT06111482Updated Nov 1, 2023

Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.

An interventional study of Intense pulsed light. and Radiofrequency microneedling device in Dermatologic Conditions, sponsored by Cynosure, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Cynosure, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Study summary

The goal of the energy-based devices used in this study is to evaluate their safety and performance to treat unwanted dermatologic conditions.

Read the detailed description

Up to 50 subjects will be enrolled at 1 study center. Subjects will be enrolled into 4 groups: Group A, Group B, Group C, or Group D. Subjects may enroll in more than one group, however the last treatment in the previous group would be at least 30 days before the subject is enroll in the next group if treatment area is the same.

02

Conditions studied

  • Dermatologic Conditions

Browse trials for

03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A healthy male or female 22 years of age or older.
  • Willing to undergo at least 1 treatment with the study device(s).
  • Understands and accepts obligation not to receive any other procedures in the treatment area through the length of the study.
  • Understands and accepts the obligation and is logistically able to be present for all visits.
  • Is willing to comply with all requirements of the study and sign the informed consent document

Exclusion criteria

Exclusion Criteria:

  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  • Takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
  • Is using systemic steroids (e.g., prednisone, dexamethasone) prior to or during the course of treatment.
  • Is receiving or has received gold therapy.
  • Is taking medications that alter the wound-healing response or has a history of healing problems.
  • Has an active localized or systemic infection, or an open wound in area being treated.
  • Has a significant systemic illness, such as lupus, or an illness localized in area being treated.
  • Has a seizure disorders triggered by light.
  • Has a history of skin photosensitivity disorders.
  • Has a history of hypertrophic scars or keloid formation.
  • Has a history of radiation therapy in area to be treated.
  • Received fillers or neurotoxin injections in the treatment area within the past 2 weeks.
  • Has had a chemical or mechanical epilation within the last six weeks.
  • Currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months to entering this study.
  • Has any condition or is in a situation which in the investigator's opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Radiofrequency Device Only:

  • Has a Pacemaker
  • Has any embedded electronic devices that give or receive a signal.
  • Has electronic implants, such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant.
  • Is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area.
  • Has nerve insensitivity to heat in the treatment area or in the neutral pad placement area.
  • Is allergic to topical anesthetic
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    IPL only

    Group A will be treated with an intense pulsed light (IPL) device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar IPL device that is cleared for use by the FDA.

    Device: Intense pulsed light.

  • Experimental
    RF Microneedling Only

    Group B will be treated with a radiofrequency (RF) microneedling device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF microneedling device that is cleared for use by the FDA.

    Device: Radiofrequency microneedling device

  • Experimental
    RF Only

    Group C will be treated with an RF device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF device that is cleared for use by the FDA.

    Device: Radiofrequency device

  • Experimental
    Combination

    Group D will receive combination treatments and will be treated with 2 or more of the study devices.

    Device: Intense pulsed light. · Device: Radiofrequency microneedling device · Device: Radiofrequency device · Device: Combined energy devices

Interventions

  • DeviceIntense pulsed light.

    The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

  • DeviceRadiofrequency microneedling device

    The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

  • DeviceRadiofrequency device

    The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

  • DeviceCombined energy devices

    The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

05

What researchers measure

Primary outcomes

  1. Maximum pain reported during treatment.

    The maximum pain during treatment per each device will be reported on a scale of 0(none) to 10 (maximum intolerable pain). This pain is recorded during when the patient is actively treated (when the patient comes in and receives a treatment from the device).

    Time frame: procedure (during device treatment)]

06

Study locations

1 of 1 sites recruiting
  • Cynosure
    Westford, Massachusetts 01886, United States
    • Sean Doherty · Contact
    Recruiting
07

Registry details

Key details

Study ID
NCT06111482
Lead sponsor
Cynosure, Inc.
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Sep 28, 2023
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
Nov 1, 2023

Study contacts

Jamie Trimper
Contact
jamie.trimper@cynosure.com
9782564200
Sean Doherty
principal investigator · Cynosure, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion